Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China

Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China

Introduction Patients with clinically significant portal hypertension (CSPH) are recommended to be treated with non-selective beta-blockers (ie, carvedilol) to prevent the first hepatic decompensation event by the renewing Baveno VII consensus. CSPH is defined by hepatic venous pressure gradient (HV...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Li, Yan Wang, Fang Wang, Tianyu Liu, Xiao Liang, Yiling Li, Xiaolong Qi, Liting Zhang, Ping Chen, Jian Fan, Ju Huang, Zhujun Cao, Xiaofeng Wu, Chuan Liu, Xiaoguo Li, Zhongji Meng, Da Zhu, Qing-Lei Zeng, Wei Gou, Jiaojian Lv, Qingge Zhang, Zhaowei Tong, Junliang Fu, Cidan Zhuoga, Dong Ji, Shuairan Zhang, Yu-Jun Wong, Xuan Liang, Shengjuan Hu, Guohong Ge, Mingxing Huang, Tao Ren, Deping Ding, Basang Zhuoga, Dianjie Dang, Liang Miao, Zhaomin Song, Xingguo Xiao, Huili Wu, Kai Jiang, Youfang Gao, Lan Ma, Tao Fang, Yuehua Wang, Qianhua Zhang, Yufang Wei, Zhongsi Hong, Yuemin Nan
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/7/e081623.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items